KRX Bio Technology Transfer Index

The Annual General Meeting of Shareholders is scheduled for March 26, 2026, to re-appoint CEO Park Sung-su and add new business purposes; analysts estimate these routine governance matters will result in a 1-5% price impact scheduled.

The 15th Annual General Meeting of Shareholders including CEO re-appointment on March 26, 2026 scheduled.

The second-largest shareholder, holding a 5.05% stake, announced on March 19, 2026, their intention to vote against the re-election of the CFO at the upcoming general meeting, citing a lack of shareholder-friendly policies; a 5-10% price impact is expected.

A conflict with the Korea Pharmaceutical Distribution Association escalated around March 18, 2026, over a new 'hub wholesaler' policy; analysts estimate the potential boycott and sales disruption will cause a price impact of 5% or more expected.

Partner NovaBridge Biosciences confirmed a potential accelerated approval pathway for gastric cancer treatment Givastomig (ABL111) following a Type B meeting with the U.S. FDA on March 17, 2026. This regulatory milestone for a lead asset is estimated to have a high market impact.

Joint venture Mentis Care to begin joint research with Emory University on March 17, 2026, for AI-based seizure detection expected.

Announced a plan for a record-high cash dividend of 2,000 KRW per common share to be approved at the March 31, 2026 AGM; medium importance due to positive impact on shareholder value, scheduled.

Announced on March 16, 2026, the agenda for the Annual General Meeting scheduled for March 31, 2026, which includes a proposal to transfer 80 billion KRW to retained earnings for future dividends and establish an audit committee; a 1-5% price impact is expected.